FIELD: pharmacology.
SUBSTANCE: group of inventions is an ophthalmic composition containing cyclosporin A of form 2 and any hydrogel where cyclosporin of form 2 is characterized by peaks when scanned with X-ray diffractometer with the radiation of Cu Kα, 2θ: 7.5, 8.8, 10.2, 11.3, 12.7, 13.8, 14.5, 15.6 and 17.5; as well as a method to treat the condition selected from the following: dry eye syndrome, blepharitis, meibomian gland disease, violation of corneal sensitivity, allergic conjunctivitis, atopic keratoconjunctivitis and pterygium, including a stage of administration of said composition to the patient, who has such a condition.
EFFECT: increased bioavailability, reduced foreign body sensation and achieved high stability.
6 cl, 8 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AUTOCLAVABLE FORM 2 CYCLOSPORIN A PORTION | 2012 |
|
RU2630970C2 |
| CYCLOSPORINE SUSPENSIONS A OF FORM 2 | 2012 |
|
RU2641963C2 |
| METHOD OF TREATING INFLAMMATIONS OF ANTERIOR EYE SEGMENT | 2013 |
|
RU2513597C1 |
| METHOD FOR TREATMENT OF HEAVY FORMS OF DRY KERATOCONJUNCTIVITIS | 2016 |
|
RU2621553C1 |
| CRYSTALLINE FORM OF CYCLOSPORINE A, METHODS FOR PREPARATION AND METHODS FOR USE THEREOF | 2012 |
|
RU2602062C2 |
| SUSPENSION COMPOSITIONS OF CYCLOSPORINE A FOR SUBCONJUNCTIVAL AND PERIOCULAR INJECTION | 2015 |
|
RU2713953C2 |
| METHOD OF AGENT SCREENING, SUITABLE FOR TREATMENT OF DRY EYE SYNDROME AND/OR INJURY OF CORNEA AND CONJUNCTIVA, PHARMACEUTICAL COMPOSITION, OBTAINED BY THEREOF | 2010 |
|
RU2564912C2 |
| INTRAOCULAR DRUG DELIVERY SYSTEMS | 2007 |
|
RU2440102C2 |
| METHOD FOR ESTIMATING THE FUNCTIONAL CONDITION OF THE LACRIMAL GLAND IN SARCOIDOSIS | 2017 |
|
RU2673635C1 |
| FORM OF 2 CYCLOSPORIN A AND METHOD OF ITS PRODUCTION | 2012 |
|
RU2635547C2 |
